RxDoctor Payments DataLook up a doctor →

Michael Verni, MD

Urology · Las Vegas, NVNPI 1376516864

Payments from drug & device makers

$79,816in general payments, 2019–2025

Across 343 payments — averaging $232.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Urogen Pharma, Inc.$66K
  • Olympus America Inc.$4K
  • Neotract Inc.$2K
  • Astellas Pharma US Inc$1K
  • Teleflex LLC$1K
  • Intuitive Surgical$557
  • plus $5K from 41 others
$352in research payments, 2019–2025

Across 1 payment — averaging $352.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Urogen Pharma, Inc.$352

What the payments were for

  • Consulting fees$3,88524%
  • Speaking & faculty fees$1,60010%
  • Travel & lodging$1,3328%
  • Food & beverage$8,61054%
  • Education$5934%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$79,816 in reported general payments places this provider in the 90th percentile of 63 urology providers in Nevada.

See all urology providers in Nevada

Medicare billing

Part B allowed, 2024
$431,557
Medicare patients
637
Services billed
5,715

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide18$281,986
MyrbetriqMirabegron37$42,743
Dutasteride201$8,441
Tamsulosin Hcl426$7,567
Potassium Citrate ErPotassium Citrate27$4,201
Solifenacin Succinate58$3,604
Alfuzosin Hcl ErAlfuzosin Hcl116$2,757
Oxybutynin Chloride ErOxybutynin Chloride61$2,439
Silodosin15$1,181
Testosterone15$1,034
Finasteride47$840
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim167$338
Ciprofloxacin Hcl85$253
Ibuprofen28$42

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,356$324,72955 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 63 urology providers in Nevada.

Other urology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →